Eli Lilly (LLY) Stock: FDA Greenlights Foundayo as GLP-1 Market Expansion Accelerates

TLDR

• Eli Lilly dips as FDA clears Foundayo for obesity treatment market

• Foundayo approval boosts oral GLP-1 space despite side effect risks

  

• New GLP-1 pill expands options but faces tolerability concerns

• Eli Lilly strengthens obesity pipeline with Foundayo launch

• Oral GLP-1 race heats up as FDA backs Lilly’s new treatment

Eli Lilly (LLY) shares declined to $906.74, down 2.19%, after a sharp intraday sell-off and a weak recovery attempt. Meanwhile, the US Food and Drug Administration approved Foundayo, an oral GLP-1 treatment for obesity. The approval strengthens competition in the growing weight-loss drug market and expands oral treatment options.

Eli Lilly and Company, LLY

Eli Lilly Advances Oral GLP-1 Pipeline with Foundayo Approval

The FDA approved Foundayo, an oral GLP-1 agonist designed for obesity and related conditions. Consequently, Eli Lilly expanded its presence in the fast-growing weight management segment. The approval also increases the number of oral GLP-1 therapies available globally.

The GLP-1 market continues to grow rapidly due to rising obesity rates and demand for non-injectable treatments. Previously, approvals included Rybelsus in 2019 and Wegovy tablets in 2025. Therefore, Foundayo becomes the third approved oral GLP-1 option in this category.

Clinical trial results showed patients lost an average of 27.3 pounds over 72 weeks. Moreover, the drug offers flexible dosing without strict timing around meals. This feature differentiates it from competing oral therapies with stricter administration requirements.

Competitive Landscape Highlights Benefits and Side Effects

Foundayo introduces new convenience advantages compared to existing GLP-1 therapies. Studies also showed higher rates of gastrointestinal side effects during trials. These effects included nausea, vomiting, and digestive discomfort in several participants.

More patients discontinued Foundayo compared to semaglutide-based treatments. This trend indicates tolerability challenges despite strong weight-loss outcomes. Balancing effectiveness and side effects remains critical in the oral GLP-1 segment.

Global revenue data highlights strong market potential for oral GLP-1 drugs. Rybelsus generated $3.5 billion in 2025, yet represented less than 5% of total GLP-1 sales. Oral therapies still offer significant expansion opportunities within the broader market.

Lexaria Positions Technology to Enhance Drug Delivery Efficiency

Lexaria Bioscience continues to position its DehydraTECH platform as a solution to reduce side effects. The company has tested the technology with multiple GLP-1 compounds over the past two years. These include semaglutide, liraglutide, and tirzepatide in oral formulations.

Results showed reduced adverse events compared to standard formulations in several studies. For example, one trial reported a 47.9% reduction in total adverse events using DehydraTECH-processed semaglutide. This outcome supports its potential role in improving patient experience.

Lexaria plans additional studies in 2026 with new GLP-1 candidates such as retatrutide and amycretin. The company may also evaluate Foundayo using its delivery platform. Improved tolerability could become a key factor in future GLP-1 competition.

Eli Lilly’s approval marks a significant step in expanding oral obesity treatments.Side effect management remains a key challenge for broader adoption. Delivery innovations may shape the next phase of growth in the GLP-1 market.

The post Eli Lilly (LLY) Stock: FDA Greenlights Foundayo as GLP-1 Market Expansion Accelerates appeared first on CoinCentral.